enGene Therapeutics Inc.
ENGNNasdaq
$1.82
↓ -5.2%Jul 17 close · end-of-day
Price
1Y↓ -49.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$126.9M
Enterprise Value
-$131.6M
P/E
0.8
P/S
—
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
-87.8%
Dividend Yield
0.0%
Revenue (TTM)
—
Net Income (TTM)
-$126.8M
Free Cash Flow (TTM)
-$111.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-49.7%
ROIC
—
Debt / Equity
—
Net Cash
$258.5M
Return 1Y
-50.5%
Company profile
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Quebec
Earnings
ENGN Q2 2026 Earnings
Period ends 2026-04-30
MetricActualYoY
Revenue——
Diluted EPS-$0.43↓ -15.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$19.4M | -$26.1M | -$62.3M | -$123.2M |
| Net income | -$24.5M | -$99.9M | -$55.1M | -$117.3M |
| Diluted EPS | $44.30 | $151.22 | $1.46 | $2.29 |
| Operating cash flow | -$17.6M | -$24.7M | -$48.3M | -$99.2M |
| Free cash flow | -$17.7M | -$25.1M | -$49.2M | -$100.7M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.8M | -$17.5M | -$26.6M | -$27.1M | -$29.9M | -$39.5M | -$31.2M | -$32.0M |
| Net income | -$14.1M | -$15.3M | -$24.6M | -$25.8M | -$29.0M | -$37.9M | -$29.8M | -$30.2M |
| Diluted EPS | $0.32 | $0.30 | $0.48 | -$0.51 | $0.57 | $1.75 | $0.44 | -$0.43 |
| Operating cash flow | -$7.2M | -$19.6M | -$25.7M | -$22.9M | -$25.6M | -$25.0M | -$28.9M | -$30.5M |
| Free cash flow | -$7.2M | -$19.8M | -$26.0M | -$23.0M | -$26.3M | -$25.4M | -$29.1M | -$30.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 16, 2026
Jun 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.